

CANCER RESEARCH & ONCOLOGY

OCTOBER 9th ~ 10th 2019

| Date | Time | Track | Presentation Title | Speaker |
|-------|---------------------------|---|--|---|
| 9-Oct | 06:00 - 07:00 AM | Novel Cancer Therapeutics and Cancer Prevention | Multilevel Interventions in Cancer Prevention and Control: A Community-Based Translational Research Framework to Address Prostate Cancer Disparities | Brian Rivers, PhD, MPH Director of the Cancer Health Equity Institute Morehouse School of Medicine (MSM) |
| 9-Oct | 07:30 - 08:30 AM | Tumor Drug Resistance and Tumor Evolution | Keynote Presentation: Pairing protein profiling with drug screens uncovers an effective therapy against high risk leukemia | Ernesto Diaz-Flores, PhD Assistant Adjunct Professor in the Department of Pediatrics/Hematology at UCSF |
| 9-Oct | 09:00 - 10:00 AM | Novel Cancer Therapeutics and Cancer Prevention | Start at the End: A Strategy for Developing and Delivering Advanced Diagnostic Tests to improve Prostate Cancer Patient Outcomes | Stephen Pennington Professor of Proteomics, Founder, CEO and CSO Atturo's Ltd. C/O UCD Conway Institute University College Dublin |
| 9-Oct | 10:30 - 11:30 AM | Tumor Drug Resistance and Tumor Evolution | A practical guide for multiplexed ion beam imaging to reveal tumor immunobiology | Selena Ferrian Sr.Staff Scientist/LSRP3, Stanford University |
| 9-Oct | 10:30 - 11:30 AM | Novel Cancer Therapeutics and Cancer Prevention | Newly Diagnosed Ovarian Cancer: Surgical Options | Mitchel S. Hoffman, MD Full-time faculty member, Department of Gynecologic Oncology, Moffitt Cancer Center, and Professor, USF Morsani College of Medicine |
| 9-Oct | 12:00 - 01:00 PM | Molecular Guidance Versus Standard of Care | Next Steps in Personalized Medicine- Using Genomics and Imaging For Treatment Selection in Early Stage Prostate Cancer | Anson Tharayanil Medical Science Liaison (Urology), Genomic Health, Inc. |
| 9-Oct | 12:00 - 01:00 PM | Novel Cancer Therapeutics and Cancer Prevention | What is New in Surgical Management of Invasive Bladder Cancer in 2020 | Khurshid Guru, MD Surgeon, Dept of Urology, Chair, Dept of Urology, Director, Applied Technology Laboratory for Advanced Surgery, Robert P. Huben Endowed Professor of Oncology, Roswell Park Cancer Institute |

| | | | | |
|--------|---------------------------|---|--|--|
| 9-Oct | 01:30 - 02:30 PM | Tumor Drug Resistance and Tumor Evolution | Tumor processing for the isolation and visualization of Tumor Infiltrating Leukocytes | Josh Mahlios, PhD Senior Marketing Product Manager, Miltenyi Biotec |
| 10-Oct | 06:00 - 07:00 AM | Novel Cancer Therapeutics and Cancer Prevention | Highly-efficient and -specific genome editing with Cas9 nickase ribonucleoproteins in Primary T-cells | Jacob Lamberth R&D Scientist, Genome and Epigenome Editing: MilliporeSigma |
| 10-Oct | 07:30 - 08:30 AM | Novel Cancer Therapeutics and Cancer Prevention | Keynote Presentation: Cancer Prevention for the Practicing Oncologist - Recommendations for Cancer Patients and Their Families | Ernest Hawk, MD, MPH Vice President & Division Head for Cancer Prevention & Population Sciences, University of Texas MD Anderson Cancer Center |
| 10-Oct | 07:30 - 08:30 AM | Novel Cancer Therapeutics and Cancer Prevention | Keynote Presentation: Cancer Prevention for the Practicing Oncologist - Recommendations for Cancer Patients and Their Families | |
| 10-Oct | 07:30 - 08:30 AM | Novel Cancer Therapeutics and Cancer Prevention | Keynote Presentation: Cancer Prevention for the Practicing Oncologist - Recommendations for Cancer Patients and Their Families | |
| 10-Oct | 07:30 - 08:30 AM | Novel Cancer Therapeutics and Cancer Prevention | Keynote Presentation: Cancer Prevention for the Practicing Oncologist - Recommendations for Cancer Patients and Their Families | |
| 10-Oct | 07:30 - 08:30 AM | Novel Cancer Therapeutics and Cancer Prevention | Keynote Presentation: Cancer Prevention for the Practicing Oncologist - Recommendations for Cancer Patients and Their Families | |
| 10-Oct | 07:30 - 08:30 AM | Novel Cancer Therapeutics and Cancer Prevention | Keynote Presentation: Cancer Prevention for the Practicing Oncologist - Recommendations for Cancer Patients and Their Families | Jeffrey N Weitzel, MD Director, Clinical Cancer Genetics, Professor, Director, Cancer Screening; Prevention City of Hope |
| 10-Oct | 09:00 - 10:00 AM | Tumor Drug Resistance and Tumor Evolution | Dynamic evolution of unstable genomes: insights from in vitro experiments and cancer genome analysis | Cheng-Zhong Zhang, PhD Assistant Professor, Biomedical Informatics, Harvard Medical School , and Assistant Professor, Biostatistics & Computational Biology, Dana-Farber Cancer Institute |
| 10-Oct | 09:00 - 10:00 AM | Novel Cancer Therapeutics and Cancer Prevention | Next Generation Targets for Immuno-Oncology | Anthony Persen, PhD Sr. Director, Protein Business Unit, R&D Systems |

| | | | | |
|--------|---------------------------|---|--|--|
| 10-Oct | 10:30 - 11:30 AM | Molecular Guidance Versus Standard of Care | Transcriptional Profiling of the Pediatric Tumor Microenvironment | Troy McEachron, PhD Assistant Professor of Research, Translational Genomics, University of Southern California, Keck School of Medicine |
| 10-Oct | 10:30 - 11:30 AM | Tumor Drug Resistance and Tumor Evolution | Whole genome imaging for sensitive and accurate analysis of structural variations in cancer | Sven Bocklandt, PhD Sr. Director of Scientific Affairs & Marketing, Bionano Genomics |
| 10-Oct | 12:00 - 01:00 PM | Tumor Drug Resistance and Tumor Evolution | Tumor Mutation Burden: Challenges and opportunities of measuring and interpreting tumor mutational burden for patient care | Ravindra Kolhe, MD, PhD Associate Professor, Pathology; Associate Director, Residency Program; Medical Director, Cytogenetics Laboratory AUMC. |
| 10-Oct | 01:30 - 02:30 PM | Molecular Guidance versus Standard of Care | Precision oncology: Biomarkers for treatment selection in metastatic castration resistant prostate cancer | Tian Zhang, MD, MHS Assistant Professor of Medicine, Division of Medical Oncology, Department of Medicine, Duke Cancer Institute |